Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


American Diabetes Association Scientific Sessions, In Brief

Executive Summary

Bristol/AstraZeneca release saxagliptin results: Dipeptidyl-peptidase-4 inhibitor demonstrates statistically significant improvement in glycemic control in patients with type 2 diabetes compared to metformin alone, Bristol-Myers Squibb and AstraZeneca report in the first presentation of Phase III data on saxagliptin June 25 during American Diabetes Association scientific sessions in Chicago. Results showed that after 24 weeks, patients taking saxagliptin and metformin had a statistically significant decrease in HbA1C levels compared to the metformin alone, the primary endpoint. Reductions in HbA1C were 0.73 percent, 0.83 percent and 0.72 percent in patients taking 2.5 mg, 5 mg and 10 mg doses, respectively. Bristol and AstraZeneca have said they intend to submit an NDA for the drug in mid-2008. Firms signed a deal worth $1 billion in January to co-develop diabetes therapies (1"The Pink Sheet" Jan. 15, 2007, p. 16). Last October, Merck's Januvia (sitagliptin) became the first DPP-4 inhibitor to be approved by FDA (2"The Pink Sheet" Oct. 23, 2006, p. 6)...

You may also be interested in...

Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis

FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said

Bristol/Astra Diabetes Deal Further Indicates Bristol Will Stay Independent

Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged

Januvia Clears FDA; Sitagliptin Has “Neutral Effects” On Weight, Agency Says

Merck's dipeptidyl peptidase IV inhibitor Januvia has no significant effect on weight, FDA said after approving sitagliptin for type 2 diabetes Oct. 16




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts